18
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What proportion of a rural population in eastern Uganda has been infected and reinfected with SARS-CoV-2?

          Findings

          In this cohort study of 441 participants, by the end of the SARS-CoV-2 Delta wave and before the widespread availability of vaccination, 67.7% of the cohort study population had been infected with SARS-CoV-2. During the subsequent Omicron wave in early 2022, 84.8% of unvaccinated, previously seronegative individuals were infected for the first time, and 50.8% of unvaccinated, already seropositive individuals were likely reinfected.

          Meaning

          These results contribute to a growing body of seroprevalence data from Africa suggesting that there are very high SARS-CoV-2 infection rates despite low case ascertainment.

          Abstract

          This cohort study estimates SARS-CoV-2 seroprevalence, attack rates, and reinfection in rural eastern Uganda using serologic surveillance from 2020 to early 2022.

          Abstract

          Importance

          Estimating the true burden of SARS-CoV-2 infection has been difficult in sub-Saharan Africa owing to asymptomatic infections and inadequate testing capacity. Antibody responses from serologic surveys can provide an estimate of SARS-CoV-2 exposure at the population level.

          Objective

          To estimate SARS-CoV-2 seroprevalence, attack rates, and reinfection in eastern Uganda using serologic surveillance from 2020 to early 2022.

          Design, Setting, and Participants

          This cohort study was conducted in the Tororo and Busia districts of eastern Uganda. Plasma samples from participants in the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda Border Cohort were obtained at 4 sampling intervals: October to November 2020, March to April 2021, August to September 2021, and February to March 2022. Each participant contributed up to 4 time points for SARS-CoV-2 serology, with almost half of all participants contributing at all 4 time points, and almost 90% contributing at 3 or 4 time points. Information on SARS-CoV-2 vaccination status was collected from participants, with the earliest reported vaccinations in the cohort occurring in May 2021.

          Main Outcomes and Measures

          The main outcomes of this study were antibody responses to the SARS-CoV-2 spike protein as measured with a bead-based serologic assay. Individual-level outcomes were aggregated to population-level SARS-CoV-2 seroprevalence, attack rates, and boosting rates. Estimates were weighted by the local age distribution according to census data.

          Results

          A total of 1483 samples from 441 participants living in 76 households were tested. Of the 441 participants, 245 (55.6%) were female, and their mean (SD) age was 16.04 (16.04) years. By the end of the Delta wave and before widespread vaccination, adjusted SARS-CoV-2 seroprevalence was 67.7% (95% credible interval [CrI], 62.5%-72.6%) in the study population. During the subsequent Omicron wave, 84.8% (95% CrI, 67.9%-93.7%) of unvaccinated, previously seronegative individuals were infected for the first time, and 50.8% (95% CrI, 40.6%-59.7%) of unvaccinated, already seropositive individuals were likely reinfected, leading to an overall seropositivity of 96.0% (95% CrI, 93.4%-97.9%) in this population. These results suggest a lower probability of reinfection in individuals with higher preexisting antibody levels. There was evidence of household clustering of SARS-CoV-2 seroconversion. No significant associations were found between SARS-CoV-2 seroconversion and gender, household size, or recent Plasmodium falciparum malaria exposure.

          Conclusions and Relevance

          In this cohort study in a rural population in eastern Uganda, there was evidence of very high SARS-CoV-2 infection rates throughout the pandemic inconsistent with national level case data and high reinfection rates during the Omicron wave.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Ultra-Sensitive Detection of Plasmodium falciparum by Amplification of Multi-Copy Subtelomeric Targets

          Introduction Accurate and sensitive detection of malaria parasites is a key factor in planning, targeting, and evaluating malaria control efforts, and requires different strategies at different elimination stages [1–3]. One major challenge is the identification of remaining reservoirs of human-to-mosquito transmission in asymptomatic individuals carrying low-density infections. The true extent of this predominantly submicroscopic reservoir became better defined with the wider application of molecular detection techniques in epidemiological studies [4,5], and its relevance to sustained malaria control has been brought into focus [1–3]. It was recently estimated that submicroscopic but PCR-detectable infections make up 20% of all malaria infections in high-transmission areas and as much as 70% in low-endemic areas, where they contribute 40% of all transmission to mosquitoes [5]. Mass drug administration (MDA) interventions include treatment of these undetected carriers and can thereby reduce parasite prevalence for several months in low- to moderate-prevalence settings, with even longer effects predicted at low transmission levels [6,7]. According to modeling predictions, mass screening and treatment (MSAT) strategies have a lower impact than MDA-based interventions [7], as MSAT is limited by the sensitivity of the diagnostic tool used. A recent study in Burkina Faso found no sustained effect of anti-malarial treatment on incidence of clinical episodes 9 mo after MSAT using conventional diagnosis based on rapid diagnostic test (RDT) [8]. This finding is likely attributable to the large proportion of undetected low-density infections. The true parasite burden could be better defined using nucleic-acid-based diagnostics, but even then, very-low-density infections might be missed. Such low-density infections might be particularly prevalent in areas with a recent and drastic decline in the force of infection of Plasmodium falciparum, where high parasite densities and disease are controlled by residual immunity. As more countries successfully reduce malaria prevalence [9], the proportion of low-density infections can be expected to rise, and more sensitive diagnostics that surpass even conventional PCR are urgently needed to detect potential hidden reservoirs. Of the current molecular detection methods available for malaria diagnosis (summarized in Table 1), RNA-based techniques such as quantitative reverse transcription PCR (qRT-PCR) [10–12], nucleic acid sequence-based amplification (NASBA) [13–15], and ELISA-like hybridization assays [16] reach the highest sensitivities by targeting the highly abundant 18S small subunit ribosomal RNA (18S rRNA). However, because of the unstable nature of RNA, these assays require dedicated and controlled sample collection and storage, and thus have only a limited application in field settings. DNA-based techniques are generally more field-adaptable and include nested PCR [17–22], quantitative PCR (qPCR) [23–31], loop-mediated isothermal amplification (LAMP) [32–35], isothermal recombinase polymerase amplification (RPA) [36], and alternative PCR-based detection methods [19,37–41]. Of the DNA-based assays, only qPCR allows one to robustly quantify copy numbers of the template DNA in the reaction as a measure of parasite load in the sample. 10.1371/journal.pmed.1001788.t001 Table 1 Assay characteristics and limit of detection (LOD) of published P. falciparum detection assays. Method Template Molecule Target Gene Quantification LOD (Parasites/μl Blood) Reference Nested PCR DNA 18S rRNA, dhfr-ts, 28S rRNA, stevor No 0.1–10 [17–22] PCR DNA mitochondrial DNA No 0.5 [42] qPCR DNA 18S rRNA, cox1, cytb Yes 0.02–3 [23–31] PCR-based DNA 18S rRNA, cox1 Yes/No 0.5–1 [19,37–41] LAMP a DNA 18S rRNA, mitochondrial DNA No 1–10 [32–35] RPA a DNA 18S rRNA No 4 [36] qRT-PCR RNA 18S rRNA Yes 0.002–0.02 [10–12] (QT-)NASBA a RNA 18S rRNA Yes/No 0.02 [13–15] aIsothermal amplification process. QT-NASBA, quantitative NASBA. Due to the lower number of target molecules in the sample, DNA-based techniques have a reduced sensitivity compared to their RNA-based counterparts, but sampling for DNA-based diagnosis is more robust. The most prominent molecular marker is the 18S rRNA gene, present at 5–8 copies per genome, depending on the parasite strain [43]. In recent years, several attempts have been made to increase DNA-based PCR sensitivity by sampling larger blood volumes and concentrating the DNA [44], or choosing mitochondrial [19,27,32,42] or nuclear multi-copy PCR targets [40,45]. Already in 1997, Cheng et al. designed a nested PCR that detected the conserved region of the subtelomeric stevor gene group, with many copies per genome [46], which had improved sensitivity over single-copy PCRs [47]. We have taken this approach further and have chosen high-copy subtelomeric sequences with the widest possible chromosomal distribution to develop novel qPCR assays for highly sensitive detection and quantification of P. falciparum in low-density infections. The telomere-associated repetitive element 2 (TARE-2) is a 1.6-kb-long block consisting of ten to twelve 135-bp repeat units with slightly degenerate sequences, interspersed by two 21-bp sequences [48,49]. The TARE-2 repeat is present at 24 of 28 subtelomeres in the 3D7 culture strain [49], which amounts to approximately 250–280 copies per genome, and is specific to P. falciparum strains [48]. The var gene family is located primarily in the subtelomere and was chosen to develop a second qPCR with a multi-copy target. The genome of the 3D7 culture strain harbors 59 var genes [49], and an estimated 50–150 copies are present in other parasite lines [50,51]. var genes encode the P. falciparum erythrocyte membrane protein 1 (PfEMP1) and possess a transmembrane domain and one intron, with exons 1 and 2 encoding the extra- and intracellular parts of PfEMP1. In contrast to the highly variable extracellular domain, the intracellular var gene acidic terminal sequence (varATS) comprises some well-conserved stretches and can thus be targeted by qPCR [50,51]. With the aim of increasing test sensitivity at least 10-fold and improving the robustness of parasite detection at low densities, we developed two novel qPCR assays using the multi-copy TARE-2 and varATS sequences as targets. We then investigated the potential of both assays to detect ultra-low-density infections that are beyond the detection limit even of 18S rRNA qPCR. We further hypothesized that the abundance of the PCR target in the parasite genome would counterbalance the diluting effect of sample pooling, and thus tested the suitability of our assays for application to sample pools. Methods Ethical Approval Field samples used for these analyses were derived from a cohort study conducted in Maprik District, Papua New Guinea (PNG), from 17 August 2009 to 20 May 2010 [11] and a cross-sectional survey conducted in Rufiji, Tanzania (TZ), in 2013. Scientific approval and ethical clearance for the PNG cohort study was obtained from the Medical Research and Advisory Committee of the Ministry of Health in PNG (MRAC no. 09.24) and the Ethics Commission of Basel Land and Basel Stadt (no. 237/11). Approval for the TZ cross-sectional study was obtained from the Institutional Review Board of the Ifakara Health Institute, Dar es Salaam, TZ (no. 13-2013). Informed consent was obtained from all study participants in PNG and TZ, for children from parents or legal guardians prior to sampling. Primer Design and qPCR Conditions For varATS primer design, all 59 varATS sequences per P. falciparum genome (strain 3D7; PlasmoDB) were aligned using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). Within the size-polymorphic varATS domain (size range 1–1.5 kb), the most conserved domain was selected for primer and MGB (minor groove binder) probe design. One wobble each was inserted into the forward primer and probe to improve annealing, whereas the reverse varATS primer matched very well with all 3D7 varATS sequences. We expect that only about 40% of 3D7 sequences match sufficiently well with the selected oligonucleotides to yield an amplification product. Attempts to further increase assay sensitivity by using additional wobbles and combinations of primers were not successful. Primer and probe sequences, as well as qPCR mixes and cycling conditions, are listed in S1 Table. The TARE-2 repeat region was identified in the genome of P. falciparum strains 3D7 (National Center for Biotechnology Information) and IT (PlasmoDB) using the Tandem Repeats Finder tool (http://tandem.bu.edu/trf/trf.html). TARE-2 sequences of other P. falciparum strains were retrieved by BLAST (http://blast.ncbi.nlm.nih.gov) search using 3D7 and IT repeat units. All repeat units were aligned using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/), and primers were designed on the most conserved stretches so that eight nucleotides prior to the 3′ end matched with the majority of repeat sequences. One wobble was inserted into each primer for better annealing. Owing to repeat degeneration and therefore difficult probe design, probe-free SYBR Green–based real-time quantification of amplicons was chosen. Primer sequences and qPCR reaction and cycling conditions are specified in S1 Table. The melt curves of amplicons were inspected in each experiment to detect false positivity. True positive samples differed clearly from primer dimer and unspecific PCR products based on the amplicon’s melting temperature (T m; S1 Fig). Samples were quantified using a standard curve of plasmid (varATS) or parasite genomic DNA (gDNA; TARE-2). As varATS standard, the varATS amplicon was amplified from 3D7 gDNA and inserted into the TOPO TA vector (Invitrogen). The purified plasmid was diluted to 106, 104, and 102 plasmids/μl in TE buffer. As TARE-2 standard, gDNA of a 10-fold dilution of ring-stage 3D7 parasite culture was used (6.8 × 103 to 6.8 × 10−2 parasites/μl; described in S1 Text). The reference 18S rRNA qPCR was performed as described previously [11,23], using a MGB probe (6FAM-5′-ACGGGTAGTCATGATTGAGTT-3′-NFQ-MGB) in a total volume of 12 μl. DNA volume matched that of varATS and TARE-2 qPCRs. The amount of target DNA in each sample was calculated from the C t value using a plasmid standard curve as described above (18S rRNA amplicon inserted in TOPO TA vector [Invitrogen]). pfs25 qRT-PCR for gametocyte detection was performed as described previously [11]. Analytical Specificity and Sensitivity The analytical specificity of the TARE-2 and varATS qPCRs was assessed both in silico using BLAST search and experimentally using human gDNA from a healthy, malaria-free volunteer and P. malariae and P. ovale gDNA (three archived anonymized clinical patient samples each). No amplification from non-falciparum Plasmodium or human DNA was observed using the varATS and TARE-2 qPCRs. For assessment of P. vivax cross-reactivity, 14 samples with a low to medium number of genomic P. vivax 18S rRNA copies (22–393 Pv18S rRNA copies/μl; light microscopy [LM]: 0–219 parasites/μl) were selected from a previously analyzed sample pool [11]. All 14 selected P. vivax DNA samples had been diagnosed P. falciparum–negative by A18S qRT-PCR. All 14 samples were varATS- and TARE-2-negative. Analytical sensitivity and qPCR efficiency were validated on dilution rows of (i) in vitro cultured ring stages (3D7 strain) and (ii) the WHO international standard for P. falciparum DNA nucleic acid amplification techniques (National Institute for Biological Standards and Control, UK) [27,52]. Details on generation of the dilution rows are presented in S1 Text. TARE-2 and varATS qPCR efficiencies, determined on the 3D7 culture dilution row, were comparable to that of 18S rRNA qPCR; however, all qPCR efficiencies were slightly outside the desirable efficiency range of 90%–105% (Table 2). Efforts to optimize qPCR efficiency by varying primer concentration, annealing temperature, and qPCR volume were not successful. 10.1371/journal.pmed.1001788.t002 Table 2 qPCR details and efficiencies of the 18S rRNA, varATS, and TARE-2 assays. Assay Slope Efficiency Intercept a R 2 Platform Amplicon Length b Amplified Copy Numbers in Genome 18S rRNA −3.63 88.5% 41.09 1.0 TaqMan 221 bp 3 varATS −3.63 88.6% 34.50 1.0 TaqMan 65 bp <59 c TARE-2 −3.75 84.7% 32.08 0.97 SYBR Green 93 bp <250–280 c aIntercept equals the C t value of the DNA equivalent of five parasites added to the qPCR reaction. bLength of consensus sequence. cPolymorphism in primer binding sites likely does not permit efficient amplification of all genomic copies. Number of target sequences present in parasite genomes from field samples cannot be determined in absence of the respective genome data. Field Samples and Nucleic Acid Extraction In a pilot study, 60 DNA samples from PNG were used for assay validation. They were selected from a larger pool of previously analyzed samples based on their positivity in 18S rRNA qPCR (33 positives, 27 negatives), and we used 18S rRNA copy numbers in these samples to select a wide range of parasite densities [11]. DNA of PNG samples was extracted using the FavorPrep 96-well Genomic DNA Extraction Kit (Favorgen) from blood cell fractions of 50–150 μl, eluted in 200 μl of elution buffer, and stored at −20°C. The 498 TZ samples were age-stratified randomly selected from the larger cross-sectional sample set, so that each age category contained at least 40 samples. We intended to estimate the overall proportion of P. falciparum–positive individuals by each test with a precision given by a CI of ±5%. Samples were collected as 50 μl of whole blood in 250 μl of RNAprotect Cell Reagent (Qiagen) to stabilize RNA. RNA extraction was performed as previously described [11]. DNA was co-extracted during RNA extraction using the RNeasy Plus 96 Kit (Qiagen). DNA was recovered from the gDNA eliminator column after two washing steps according to the QIAamp 96 DNA Blood Kit protocol (500 μl of AW1 buffer, 500 μl of AW2 buffer) and eluted in 100 μl of AE elution buffer. TARE-2, varATS, and 18S rRNA qPCR were performed once on each TZ DNA sample. If sample positivity did not agree between the three qPCR assays, each qPCR was repeated in duplicate for the discrepant sample, yielding a total of three qPCR replicates for all assays in the discrepant samples. Samples were defined as positive for varATS, TARE-2, or 18S rRNA qPCR if two out of three replicates were positive. For gametocyte detection, pfs25 qRT-PCR was performed as previously described using 4 μl of RNA [11]. Generation of Pooled Samples Low-density P. falciparum–positive samples (<2 parasites/μl by TARE-2 qPCR, LM negative) were selected from the TZ collection and mixed with four or nine P. falciparum–negative blood samples to create pools of five or ten samples. Negative samples were prepared by mixing 50 μl of blood from a malaria-negative blood donor with 250 μl of RNAprotect Cell Reagent (Qiagen) to permit simultaneous DNA and RNA isolation. Per sample, 100 μl of whole blood in RNAprotect Cell Reagent was added to the pool, resulting in a total sample volume of 500 μl or 1 ml (for five- and ten-sample pools, respectively). DNA was extracted from the entire volume of these pools using the RNeasy Plus 96 Kit (Qiagen) as described above, and DNA was eluted in 100 μl (five-sample pools) or 200 μl (ten-sample pools). In total we generated 20 pools of five samples, five of which contained a P. falciparum–positive sample, and ten pools of ten samples, two of which contained a positive sample. Statistical Analyses Data analysis was performed using R v3.0.2 statistical software. The Mann-Whitney-Wilcoxon test was used to compare for each parasite population (TZ and PNG) the mean T m of the specific amplicon versus primer dimer. The LOD of qPCR assays, i.e., the concentration at which a sample is detected with 95% confidence, was calculated at using probit analysis of the dilution row results. Proportions of samples positive for the TARE-2, varATS, and 18S rRNA qPCRs in the TZ and PNG datasets were compared using McNemar’s Chi2 test. Correlations of parasite quantity per microliter or template copy number per microliter between assays were calculated using Pearson’s product-moment correlation. Results Limit of Detection of varATS and TARE-2 qPCRs Probit analysis was used to determine the LOD, i.e., the concentration at which a sample would be detected with 95% confidence (Fig 1), based on qPCR results from dilution rows of parasite culture and WHO standard material (S3 Table). The varATS and TARE-2 qPCRs were at least 10× more sensitive than standard 18S rRNA qPCR and reached LODs, calculated on the two different dilution rows, of 0.06 and 0.15 parasites/μl (varATS; CI95 [0.02–1.07] and [0.05–4.37]) and 0.03 and 0.12 parasites/μl (TARE-2; CI95 [not defined] and [0.04–2.06]). Probit analysis of the TARE-2 results using the WHO standard dilution row did not yield a 95% CI because of the steep slope of the regression line. The LOD of 18S rRNA qPCR was calculated at 1.57 parasites/μl (CI95 [0.28–626.73]). The TARE-2 and varATS assays can therefore robustly detect as few as 6–24 and 12–30 parasites in 200 μl whole blood, respectively, which is the typical volume normally processed for DNA extraction from fingerprick blood samples without sample concentration. 10.1371/journal.pmed.1001788.g001 Fig 1 Limit of detection of TARE-2, varATS, and 18S rRNA qPCRs. Dashed lines: based of serial dilution of WHO standard material [52]. Continuous lines: based on serial dilution of ring-stage 3D7 in vitro culture. par, parasites. Detection of Ultra-Low-Density Infections in Maprik District, Papua New Guinea As pilot study, we compared the ability of the three qPCRs to detect low-density P. falciparum infections in 60 DNA samples from PNG. All 33 samples that were positive in 18S rRNA qPCR were also positive using both ultra-sensitive assays. Out of the 27 samples negative by 18S rRNA qPCR, four were positive in varATS qPCR (McNemar’s Chi2, p = 0.181). The same four samples plus five additional samples were positive by TARE-2 qPCR, resulting in a significant gain in sample positivity (McNemar’s Chi2, p = 0.036). Since samples were not randomly selected but chosen deliberately to include a wide parasite density range, this result does not reflect the true P. falciparum prevalence in Maprik District, PNG. Nevertheless the number of additional samples positive for P. falciparum demonstrates that a considerable proportion of infections may persist at ultra-low densities and remain undetected by standard qPCR. Prevalence of Ultra-Low-Density Infections and Gametocyte Carriage in Rufiji, Tanzania P. falciparum prevalence in Rufiji, TZ, was assessed in 498 samples randomly selected from a larger cross-sectional study conducted in 2013. P. falciparum prevalence was higher using ultra-sensitive detection methods as compared to 18S rRNA qPCR, with borderline significance (McNemar’s Chi2, p TARE-2 = 0.068, p varATS = 0.083). Prevalence values were 25% (CI95 [21%–29%]) by LM, 50% (CI95 [45%–54%]) by 18S rRNA qPCR, and 58% (CI95 [53%–63%]) by varATS qPCR or TARE-2 qPCR (Fig 2A). Applying ultra-sensitive techniques thus revealed a larger submicroscopic infection pool than detected by the routinely used molecular method. Despite a gain in prevalence of 25% over LM, 18S rRNA qPCR still underestimated the true parasite prevalence by 8% without major differences across age groups (Fig 2B). In a total of 295 P. falciparum infections, 16% (48 samples) were not detected by 18S rRNA qPCR but only by varATS or TARE-2 qPCR (Fig 2C). Agreement between assays was very good in the subset positive in 18S rRNA qPCR, with all samples positive in 18S rRNA qPCR detected also by varATS qPCR and all but two by TARE-2 qPCR. The level of agreement between TARE-2 and varATS qPCRs in this sample subgroup was also high, with 79% (38/48) of samples detected by both ultra-sensitive assays. 10.1371/journal.pmed.1001788.g002 Fig 2 P. falciparum prevalence and gametocyte carriage in Rufiji, Tanzania. (A) Overall P. falciparum prevalence by different diagnostic methods. Error bars represent 95% CIs. (B) P. falciparum prevalence based on TARE-2, varATS, and 18S rRNA qPCRs by age (in years). Error bars represent 95% CIs. (C) Venn diagram of positivity by varATS, TARE-2, and 18S rRNA qPCRs. (D) Proportion of gametocyte carriers by pfs25 qRT-PCR. Samples were categorized according to the least sensitive method that identified them as P. falciparum–positive. In total, 13 of 126 LM-positive samples were not confirmed by any qPCR, and 11 of these also were negative by RDT (SD Bioline Pan pLDH/PfHRP2), thus these samples should be considered false positive by LM. Three samples had to be excluded from the gametocyte analyses because of missing RNA data. Quantification of parasite load by varATS and TARE-2 correlated very well with 18S rRNA qPCR quantification in field samples from Rufiji (Pearson’s correlation coefficient, R 2 = 0.98, CI95 [0.97–0.98], and R 2 = 0.95, CI95 [0.94–0.96], respectively; Fig 3A), as well as with each other (R 2 = 0.97, CI95 [0.96–0.98]). Correlation of parasite load determined by qPCR and by microscopy was similar for the three assays and ranged from 0.74 (18S rRNA, CI95 [0.64–0.81]) to 0.66 (TARE-2, CI95 [0.54–0.75]; varATS: 0.68, CI95 [0.57–0.80]; Fig 4). Despite the high number of target sequences and slight sequence degeneration, quantification of parasite load is thus feasible using varATS and TARE-2 qPCRs. Parasite loads by TARE-2 qPCR in samples negative by 18S rRNA qPCR were, except for few outliers, within the lowest quartile of all parasite loads by TARE-2 quantification. The same was observed for varATS copy numbers of samples negative by 18S rRNA. When stratified by age, parasite densities or target copy numbers were low in infants up to 1 y, peaked in 2- to 3-y-old children, and decreased thereafter, with the lowest parasite loads observed in the oldest age group (Fig 3B). 10.1371/journal.pmed.1001788.g003 Fig 3 Correlation of parasite quantification using varATS, TARE-2, and 18S rRNA qPCRs and parasite densities in Rufiji, Tanzania. (A) Parasite quantities determined by ultra-sensitive assays and their correlation with 18S rRNA quantification. Quantification was done relative to copy numbers of plasmid standards (18S rRNA, varATS) or a parasite dilution row (TARE-2). Quantities of samples negative in 18S rRNA qPCR but positive in ultra-sensitive assays are shown in the left (varATS) and right (TARE-2) panels. (B) P. falciparum densities based on TARE-2, varATS, and 18S rRNA qPCRs by age (in years). The geometric mean in each age group is marked by a diamond; the median is denoted by a black line. 10.1371/journal.pmed.1001788.g004 Fig 4 Correlation of parasite quantification by the three qPCR assays and light microscopy. Parasite quantities determined by 18S rRNA (A), varATS (B), and TARE-2 (C) qPCRs and their correlation with parasite density by LM. Quantification by PCR was done relative to copy numbers of plasmid standards (18S rRNA, varATS) or a parasite dilution row (TARE-2). For quantification by LM, 200 fields of a thick film were examined, and parasite density was calculated assuming 8,000 leucocytes/μl blood. Pearson’s product-moment correlation was used to assess correlation strength, and Deming regression was used to calculate regression lines. The prevalence of gametocytes by pfs25 qRT-PCR was 40% in all study participants (CI95 [36%–45%]). The proportion of pfs25-positive samples was highest in samples that were positive by LM, of which 77% (CI95 [69%–84%], 97/126) carried gametocytes (Fig 2D). Among submicroscopic infections identified by 18S rRNA qPCR, gametocytes were detected in 63% (CI95 [55%–72%], 85/134) of samples. In samples positive only by TARE-2 and/or varATS qPCR, 40% (CI95 [26%–56%], 18/45) carried gametocytes. These observations prove that molecularly determined gametocyte carriers are not predominantly found among LM-positive individuals, but rather that an equal number of gametocyte carriers are present in study participants with submicroscopic infections. By use of a routinely used 18S rRNA assay, 16% of asexual infections and 9% of gametocyte carriers would have been missed. Performance on Sample Pools To investigate the potential of our assays for a wider application in malaria surveillance or epidemiological field studies, we tested the power of all three qPCR assays to identify P. falciparum–positive samples in pools of five or ten samples, each containing one low-density P. falciparum infection. 18S rRNA qPCR failed to identify the two positive ten-sample pools and identified only one of five positive five-sample pools. In contrast, varATS and TARE-2 qPCR correctly detected all positive five- and ten-sample pools. No amplification was observed from negative control pools. Our ultra-sensitive assays thus proved suitable for detection of low-grade infections after dilution in nine negative samples. These infections would be missed by 18S rRNA qPCR after pooling. In a setting with 2% P. falciparum prevalence, as simulated here, the cost of sample processing and detection can therefore be reduced by at least 70% without loss in sensitivity if ultra-sensitive assays are applied to pools of ten samples. Discussion Detecting Low-Density Infections Using Ultra-Sensitive Methods Is Relevant for Malaria Control Efforts Accurate data on parasite prevalence in the community are imperative for targeting antimalarial interventions and for monitoring their outcome. In this study, we provide first evidence of very-low-grade infections in individuals who had previously been considered parasite-free, even after molecular diagnosis, and show that a large proportion of these samples carry gametocytes. In Rufiji, a high-endemic area in TZ, microscopic and submicroscopic infections (by standard 18S rRNA qPCR) each amount to roughly 40% of all P. falciparum infections; 16% are of ultra-low density and detected only by TARE-2 and varATS assays. These ultra-low-density infections potentially contribute to transmission, as they represent 9% of the molecularly detected gametocyte carriers. In Maprik District, PNG, 18S rRNA qPCR failed to identify similar quantities of ultra-low-density infections. A meta-analysis of infection prevalence across the endemicity spectrum has indicated that submicroscopic infections are generally more prevalent in low-transmission settings than in high-transmission areas [5], probably as a result of a recently reduced force of infection and the long duration of asymptomatic untreated infections [53–55]. In such areas, detection of infection, rather than assessment of malaria-associated illness, could serve as a better measure of the malaria burden and a better parameter for surveillance and evaluation [1,2]. Low-density infections can be missed in cross-sectional studies even when using standard 18S rRNA qPCR because parasitemia fluctuates and may occasionally fall below the detection threshold of the assay. Waves of asexual parasitemia and gametocytemia were described in malaria therapy data [56,57]. Accordingly, scanty infections may rise in density at a later time point and increase gametocyte production to detectable levels, leading to higher transmission potential. Improved measures of prevalence using tools for reliable detection of low-density infections can contribute significant information and are important for accurate monitoring and evaluation of malaria control activities, as well as for assessing the potential for onward transmission from human hosts to mosquitoes. Gametocyte Carriage in Low-Density Infections Emphasizes Their Potential Contribution to Malaria Transmission Few studies have investigated the transmission potential of submicroscopic infections. Microscopically detectable infections with gametocyte densities below the microscopical threshold can infect mosquitoes, albeit at lower rates than microscopically gametocyte-positive samples (2.3% versus 13.2% infected mosquitoes) [58]. A meta-analysis of mosquito feeding assays conducted in several African countries showed that 27.6% of individuals who lacked microscopically detectable gametocytes were capable of infecting mosquitoes [59]. Similarly, data from the mid-20th century and from two recent studies showed that even blood from infections without any microscopically detectable parasites resulted in 0.2%–3.2% infected mosquitoes [5,60–62]. In a study performed in the Gambia, multiple parasite genotypes were detected in oocysts after feeding mosquitoes on blood seemingly carrying a clonal infection [63]. In that study, multiple gametocyte genotypes were detected in the same blood sample, suggesting that parasite clones undetectable on DNA level produced gametocytes in quantities sufficient to transmit to mosquitoes. Clustering of gametocytes, especially in infections with low gametocyte densities, has been given as a possible explanation for why such infections are able to transmit to mosquitoes [64–66]. A modeling analysis using data from Cameroon found that asexual densities did not predict the proportion of infected mosquitoes, contrary to gametocyte densities, which exhibited a complex and non-linear correlation with transmission success [58,67,68]. Taken together, the available data suggest that all infections should be viewed as potentially relevant for transmission. The relative contribution of low-density infections to forward transmission to mosquitoes hence may gain substantial importance in areas where these account for a large proportion of infections [5,58]. In our TZ setting, the majority of infections were submicroscopic and harbored 50% of gametocyte-positive samples. TARE-2 and varATS assays identified a so far ignored extent of submicroscopic infective burden, with 40% of these low-key infections carrying gametocytes. We thus argue for including ultra-low-grade infections into the evaluation of malaria interventions and for acknowledging their potential relevance for maintaining transmission, a role that urgently needs experimental clarification. Sensitivity as a Major Determinant of Prevalence Estimates: Advantages and Limitations of the TARE-2 and varATS qPCRs Our results highlight the fact that prevalence data are strongly dependent on the sensitivity of the diagnostic technique applied. Even if parasite prevalence is measured using standard qPCR protocols, many low-key infections remain undetected. Standard PCR is widely considered a molecular gold standard of malaria diagnosis complementing LM, the traditional gold standard, yet our results suggest that this notion requires revision. It becomes increasingly clear that the volume of blood analyzed [44] and the use of multi-copy markers to increase the representation of a PCR template in the amplification reaction ([19] and this study) have great influence on the prevalence outcome. Our findings shed new light on MSAT strategies for interruption of transmission in elimination settings, particularly those that rely on RDT-based diagnosis only, as it becomes clear that the ignored proportion of submicroscopic infections is even larger than anticipated. Following a recent MSAT campaign in TZ, RDT-undetected infections were given as a plausible explanation for the short-lived effect on malaria episode incidence [69]. In that study, it was estimated that more than 45% of PCR-detectable infections were missed by RDT, which, given our results, is very likely a substantial underestimation. A major task now consists in adapting molecular methods with enhanced sensitivity to meet the requirements of a robust, field-compatible diagnostic assay. Such tools are becoming increasingly important to determine the infection burden irrespective of endemicity level. We have presented here two ultra-sensitive qPCR assays for improved detection of low-grade P. falciparum infections and their application to sample pools. The varATS qPCR is very robust and highly specific, and allows fast and easy data analysis through the use of a sequence-specific probe. The TARE-2 assay is more susceptible to changes in the chemical composition of the DNA solution and requires melt curve analysis of amplicons, which is a potential drawback, particularly when performed by less-trained personnel. Both assays exhibited slightly suboptimal amplification efficiency despite all optimization efforts, possibly because of a wobble base introduced into primer and probe sequences to improve annealing to the target copies in the genome. Regardless of this inherent low efficiency, sensitivity was superior to that of 18S rRNA qPCR in field samples and on parasite dilution rows. Surprisingly, the TARE-2 qPCR did not outperform the varATS assay despite substantially higher target numbers in the genome. This might be explained by the degenerate sequence of the TARE-2 repeat units or by the clustered distribution of the repeats at chromosome ends. In the 3D7 genome, about ten TARE-2 tandem repeats are present at 24 chromosome ends, and in this arrangement, they may not be separated during DNA extraction. The 59 varATS targets of strain 3D7 also localize to chromosome ends and a few intracellular loci. We assume an equal probability for both targets to be represented in a PCR reaction, but certainly both assays surpass 18S rRNA qPCR, with three copies on different chromosomes targeted by our assay. Because of the need for advanced laboratory infrastructure and staff training, use of our TARE-2 and varATS qPCRs in their current setup is not feasible in remote field settings. However, the assays are ideally suited for use in reference laboratories, for example for quality assurance or for centralized processing of large sample numbers in sample pools. Several strategies for pooling samples for malaria surveys have been described, comprising one or several pooling steps before [70–72] or after [73,74] DNA extraction. Pooling is severely limited by its inherent diluting effect and is therefore not recommended in the Malaria Eradication Research Agenda (malERA) strategy [1]. In low-endemic settings, in particular, where pooling would be most cost- and labor-effective, submicroscopic infections are highly prevalent [5] but are most likely missed in pools because of their low densities. Our varATS and TARE-2 assays proved to be useful for testing pooled samples as they counterbalance the diluting effect through multiple marker copies per parasite. In our hands, even the lowest-density infections diluted with nine negative samples were still detectable. This high sensitivity may be further enhanced by increasing the volume of blood samples and concentrating material before qPCR [44]. The availability of ultra-sensitive assays such as our TARE-2 and varATS qPCRs makes sample pooling without loss in sensitivity feasible and allows achieving higher throughput in the context of limited resources in large-scale field studies. Once similar assays have been developed also for detecting the other human-infecting Plasmodia, blood pooling followed by multiplex PCR will further reduce the per-sample cost in studies requiring detection of all four Plasmodium species. Conclusion In conclusion, we encourage employing assays with enhanced sensitivity, such as the TARE-2 or varATS qPCRs, in any malaria survey aiming to obtain accurate prevalence data and for monitoring intervention success, and recommend them particularly for screening of community samples in areas of low endemicity. The fact that parasites are more prevalent than currently thought has consequences for malaria control efforts, some of which are based on identifying all infected individuals, and this fact must be acknowledged by all users of prevalence data such as health officials, strategy planners, and mathematical modelers. Infections of ultra-low densities in our TZ samples carried gametocytes in 40% of cases, and thus it is highly probable that they can be transmitted to mosquitoes at the time point of the survey or later. Until the infectiousness to mosquitoes of low-density infections has been clarified, applying the most sensitive tools is essential for better defining the true infection burden and informing elimination strategies. Supporting Information S1 Fig Melting temperature of TARE-2 amplicons using DNA samples from two different sources (surveys in Tanzania and Papua New Guinea). Melting temperature (T m) of true positives (as in positive control/standards) differs significantly from false positive signals (primer dimer, Welch’s t-test, p < 0.001). Owing to the degenerate character of the TARE-2 repeat unit, PCR products vary in sequence composition, which is reflected in slight variations in the T m of true positives (TZ, 68.6–72.2°C; PNG, 70.0–72.1°C). Different DNA extraction kits and dilution buffers used in the PNG and TZ surveys cause shifts in T m for both specific amplicons and primer dimer. The mean T m of true positives and primer dimer was significantly different between the PNG and TZ samples (Welch’s t-test, p < 0.001), while qPCR amplicons amplified from 3D7 DNA standard included on both the TZ and PNG qPCR plates showed no significant differences in their mean T m. The T m of specific amplicons and primer dimer was hence established separately for each of our two sets of field samples. (TIFF) Click here for additional data file. S1 Table Oligonucleotide sequences and qPCR conditions for varATS and TARE-2 assays. Primers were purchased from Eurofins. The varATS probe and all qPCR reagents were purchased from Applied Biosystems/Life Technologies. (DOCX) Click here for additional data file. S2 Table STARD checklist for reporting studies of diagnostic accuracy. (DOCX) Click here for additional data file. S3 Table Results of TARE-2, varATS, and 18S rRNA qPCRs on parasite dilution rows. (DOCX) Click here for additional data file. S4 Table Database of light microscopy and qPCR results of the Tanzanian cross-sectional study. Age_Group: in years, corresponding to Figs 2 and 3; 18SrRNA_Quantification: 18S rRNA copy numbers per microliter of blood; varATS_Quantification: varATS copy numbers per microliter of blood; TARE-2_Quantification: parasites per microliter of blood as determined by TARE-2 qPCR; LM_Quantification: parasites per microliter of blood as determined by LM; Pfs25_positivity: 1 indicates positive in pfs25 qRT-PCR, 0 indicates negative in pfs25 qRT-PCR. (XLSX) Click here for additional data file. S1 Text Generation of P. falciparum dilution rows for determining the limit of detection and qPCR efficiency. (DOCX) Click here for additional data file.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron

            The SARS-CoV-2 Omicron with increased fitness is spreading rapidly worldwide. Analysis of cryo-EM structures of the Spike (S) from Omicron reveals amino acid substitutions forging interactions that stably maintain an active conformation for receptor recognition. The relatively more compact domain organization confers improved stability and enhances attachment but compromises the efficiency of the viral fusion step. Alterations in local conformation, charge and hydrophobic microenvironments underpin the modulation of the epitopes such that they are not recognized by most NTD- and RBD-antibodies, facilitating viral immune escape. Structure of the Omicron S bound with human ACE2, together with the analysis of sequence conservation in ACE2 binding region of 25 sarbecovirus members as well as heatmaps of the immunogenic sites and their corresponding mutational frequencies sheds light on conserved and structurally restrained regions that can be used for the development of broad-spectrum vaccines and therapeutics.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure

              The Omicron, or Pango lineage B.1.1.529, variant of SARS-CoV-2 carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection from severe disease, often attributed to primed cellular immunity. We investigated T and B cell immunity against B.1.1.529 in triple mRNA vaccinated healthcare workers (HCW) with different SARS-CoV-2 infection histories. B and T cell immunity against previous variants of concern was enhanced in triple vaccinated individuals, but magnitude of T and B cell responses against B.1.1.529 spike protein was reduced. Immune imprinting by infection with the earlier B.1.1.7 (Alpha) variant resulted in less durable binding antibody against B.1.1.529. Previously infection-naïve HCW who became infected during the B.1.1.529 wave showed enhanced immunity against earlier variants, but reduced nAb potency and T cell responses against B.1.1.529 itself. Previous Wuhan Hu-1 infection abrogated T cell recognition and any enhanced cross-reactive neutralizing immunity on infection with B.1.1.529.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                15 February 2023
                February 2023
                15 February 2023
                : 6
                : 2
                : e2255978
                Affiliations
                [1 ]Division of HIV, ID, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco
                [2 ]Infectious Diseases Research Collaboration, Kampala, Uganda
                [3 ]Department of Medicine, Makerere University, Kampala, Uganda
                [4 ]Department of Medicine, Stanford University, Stanford, California
                [5 ]Department of Microbiology and Immunology, Stanford University, Stanford, California
                [6 ]Central Public Health Laboratories, Butabika, Uganda
                Author notes
                Article Information
                Accepted for Publication: December 28, 2022.
                Published: February 15, 2023. doi:10.1001/jamanetworkopen.2022.55978
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2023 Briggs J et al. JAMA Network Open.
                Corresponding Author: Jessica Briggs, MD, Division of HIV, ID, and Global Medicine, Department of Medicine, University of California San Francisco, 1001 Potrero Ave, Bldg 3, Room 525, San Francisco, CA 94110 ( jessica.briggs@ 123456ucsf.edu ).
                Author Contributions: Drs Briggs and Takahashi had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Briggs and Takahashi are co–first authors. Drs Ssewanyana and Rodríguez-Barraquer are co–last authors.
                Concept and design: Briggs, Takahashi, Arinaitwe, Nankabirwa, Kamya, Rosenthal, Dorsey, Greenhouse, Ssewanyana, Rodríguez-Barraquer.
                Acquisition, analysis, or interpretation of data: Briggs, Takahashi, Nayebare, Cuu, Rek, Zedi, Kizza, Arinaitwe, Nankabirwa, Jagannathan, Jacobson, Dorsey, Greenhouse, Ssewanyana, Rodríguez-Barraquer.
                Drafting of the manuscript: Briggs, Takahashi, Nayebare, Cuu, Kizza, Arinaitwe, Ssewanyana.
                Critical revision of the manuscript for important intellectual content: Briggs, Takahashi, Cuu, Rek, Zedi, Arinaitwe, Nankabirwa, Kamya, Jagannathan, Jacobson, Rosenthal, Dorsey, Greenhouse, Ssewanyana, Rodríguez-Barraquer.
                Statistical analysis: Briggs, Takahashi, Cuu, Arinaitwe, Rodríguez-Barraquer.
                Obtained funding: Briggs, Jagannathan, Greenhouse, Ssewanyana.
                Administrative, technical, or material support: Briggs, Nayebare, Cuu, Zedi, Kizza, Nankabirwa, Kamya, Jagannathan, Rosenthal, Greenhouse, Ssewanyana.
                Supervision: Briggs, Rek, Zedi, Arinaitwe, Nankabirwa, Rosenthal, Dorsey, Greenhouse, Ssewanyana, Rodríguez-Barraquer.
                Conflict of Interest Disclosures: None reported.
                Funding/Support: We acknowledge sources of funding support, including from the Schmidt Science Fellows, in partnership with the Rhodes Trust (to Dr Takahashi); Chan Zuckerberg Biohub Investigator program (to Drs Rodríguez-Barraquer and Greenhouse); National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grant K23AI166009 (to Dr Briggs); NIH/NIAID grant U19AI089674 (to Dr Briggs, Dr Rek, Dr Zedi, Mr Kizza, Dr Arinaitwe, Dr Kamya, Dr Jagannathan, Dr Dorsey, Dr Greenhouse, Dr Ssewanyana, and Dr Rodríguez-Barraquer); NIH/NIAID grant U01AI150741 (to Drs Takahashi, Jagannathan, Greenhouse, and Rodríguez-Barraquer); grant K43TW010365 (to Dr Nankabirwa); and NIH/National Institute of General Medical Sciences grant R35GM138361 (to Dr Rodríguez-Barraquer). This work was also supported in part by the Bill & Melinda Gates Foundation (grant INV-023690 to Drs Briggs and Greenhouse). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Data Sharing Statement: See Supplement 2.
                Additional Contributions: We thank all study participants who took part in this study. We also thank the clinical, laboratory, and data study team and the Infectious Diseases Research Collaboration for administrative and technical support. John Pak, PhD, and Wesley Wu, PhD (both at Chan Zuckerberg Biohub), generated the SARS-CoV-2 proteins used in this analysis. We acknowledge Central Public Health Laboratory and Claire Nankoma, BS (Public Health Emergency Operation Centre, Ministry of Health, Uganda), for sharing district-level COVID-19 case data. The individuals named in this section were not compensated for their work beyond their normal salaries.
                Article
                zoi221593
                10.1001/jamanetworkopen.2022.55978
                9932849
                36790811
                ffe77f0b-0d64-4788-897a-6494d794ff4e
                Copyright 2023 Briggs J et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 26 September 2022
                : 28 December 2022
                Categories
                Research
                Original Investigation
                Online Only
                Infectious Diseases

                Comments

                Comment on this article